Background {#Sec1}
==========

Alpha 1 Antitrypsin (AAT) is a glycoprotein normally present in human blood at a concentration between 90 and 180 mg/dL \[[@CR1]\]. It is encoded by the *SERPINA1* gene that is located on the long arm of chromosome 14 (cytogenetic location: 14q32.13); the gene encompasses 12.2 kb, containing 4 exons and 3 introns \[[@CR2]\]. AAT is an effective inhibitor of serine proteinases, in particular leukocytic elastase; in this capacity it exerts a protective function on various tissues, especially the lungs, against proteolytic/elastolytic damage \[[@CR3]\].

AAT is a highly polymorphic protein; over 70 sequence variants have been reported to be clinically significant and over 500 single-nucleotide variations (SNVs) identified in mutation databases. Some variants are common in certain populations such that their frequency may be maintained by a heterozygous selective advantage \[[@CR4]\]. Common alleles that fit this definition, including PI\*Z and PI\*S, are frequent in Northern Europe and Spain/Portugal respectively \[[@CR5]\].

The nomenclature (Z, S, M etc.) refers to a lettering system in which the normal common allele is designated PI\*M, and other letters refer to the isoelectric point of the protein in a pH gradient established by isoelectric focusing (IEF) -- a common method used to identify AAT variants \[[@CR1]\]. Certain relatively common variants, in particular PI\*Z and S, are associated with low levels of AAT in the circulation \[[@CR1]\]. The Z and S alleles are caused by E342K and E264V substitutions, respectively; both cause misfolding and polymerization (to a lesser extent with the S allele) of AAT \[[@CR2]\]. The Z mutation also results in retention of polymerized AAT in hepatocytes, leading to severe deficiency and liver disease, and is of special clinical interest.

Among patients of European ancestry with chronic obstructive pulmonary disease (COPD; including emphysema), 1--3% have been found to have Alpha 1 Antitrypsin Deficiency (AATD), usually due to homozygosity for PI\*Z \[[@CR6]\]. There are, however, less common deficiency alleles that can also be associated with reduced AAT levels and lung disease \[[@CR7]--[@CR9]\]. As testing and screening become more widely used, more variants associated with low AAT levels continue to be uncovered \[[@CR10]\]. Primarily, the improved identification of rare/novel variants is due to the increased use of DNA sequencing. In particular, next-generation sequencing (NGS), a far higher-throughput technology than Sanger sequencing \[[@CR11]\], has the potential to improve the diagnosis of AATD through the enhanced detection of rare/novel variants \[[@CR12]\].

We report a number of rare/novel *SERPINA1* sequence variants detected with the use of NGS in a US-wide AATD targeted detection program. To characterize the potential deleterious effects of these variants, we utilized a number of molecular modeling analyses. Our aim was to cover the whole spectrum from the nucleotide base change to the altered protein structure, and predict the clinical consequences to the patient.

Methods {#Sec2}
=======

Subjects {#Sec3}
--------

Patients were recruited from the Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania (*n* = 4) or through nationwide physician referral to the DNA~1~ Advanced Alpha-1 Screening™ program (developed and performed by Biocerna LLC, Fulton, Maryland, USA, on behalf of CSL Behring, King of Prussia, Pennsylvania, USA; *n* = 19). Blood samples on serum separator cards were collected through routine clinical testing by the treating physician and sent to Biocerna for AATD screening.

Patients were included in this study if discordance existed between the patient's AAT level and the targeted genotyping results. For these patients, NGS was used to identify rare or potentially novel genetic variants. Consent for use of laboratory data for research purposes was provided by all patients included in this study. The study was approved by the Institutional Review Board of Temple University, Philadelphia, PA.

Laboratory analyses {#Sec4}
-------------------

Data on antigenic serum AAT and c-reactive protein levels, AAT phenotype by IEF, and genetic analyses by targeted real-time polymerase chain reaction and NGS were collected for patients included in this study.

Serum AAT levels were assessed in all patients. For the four patients referred from Lewis Katz School of Medicine, quantitative analysis of antigenic serum AAT was performed by radial immunodiffusion (normal range: 150--400 mg/dL) at Temple University. For the remaining patients, antigenic AAT and CRP levels were assessed using immunoturbidimetry (normal range: 90--200 mg/dL and \< 5 mg/L, respectively) \[Roche™ AAT2 and C-Reactive Protein gen 3 immunoassay; Basel, Switzerland\] at Biocerna.

All genetic and IEF analyses were performed centrally at Biocerna. Initial qualitative assessment of AATD genotype was by real-time polymerase chain reaction targeted genotyping (TaqMan**®**: Thermo Fisher Scientific, Waltham, MA). Phenotype was investigated using IEF (Hydragel 18 A1AT IEF isofocusing kit, Sebia USA, Norcross, GA).

NGS methodology includes sequencing of *SERPINA1* 5′ and 3′ untranslated regions (UTRs), the promotor region, coding exons, introns, and splice sites. Specific target regions of the *SERPINA1* gene were amplified using the Ion AmpliSeq™ Custom Primer Pools (Thermo Fisher Scientific). The primer pools included a total of 52 amplicons containing unique PCR primers to amplify specific target sequences in each template DNA. Library preparation was performed using Ion AmpliSeq™ Library Kit 2.0--96 LV (Thermo Fisher Scientific). Sample identity was maintained using unique Ion Xpress™ Barcode Adapters (Thermo Fisher Scientific), which allowed for multiplexed sequencing analysis. Emulsion PCR was used to clonally amplify the library DNA onto the Ion Sphere™ Particles (ISP). Following ISP template amplification, the ISP-enriched template-positive library was loaded onto an Ion 314™ Chip Kit v2 (Thermo Fisher Scientific). The Ion PGM instrument was used to sequence the combined library.

Computational modeling and variant predictions {#Sec5}
----------------------------------------------

To visualize and map the locations of sequence variants in the AAT proteins, molecular modeling software UCSF Chimera (University College of San Francisco, CA) was used (Fig. [1](#Fig1){ref-type="fig"}). A linear diagram of the AAT amino acid sequence with mutation locations was also prepared (Fig. [2](#Fig2){ref-type="fig"}) using the software package ESPript \[[@CR13]\].Fig. 1Structure of AAT indicating the location of missense residues. The AAT protein (PDB code 1OPH) is shown in ribbon representation coloring according to secondary structural elements (alpha helices shown in orange, beta strands shown in light blue), and the position of missense changes showing the wildtype residue in sphere representation and labeled with the residue name and position. The purple ribbon protein is trypsinogen. The stretch of amino acids that comprise the reactive center loop are shown in green ribbon representation. A = front view; B = rear view (rotated 180 degrees about the x-axis). AAT, Alpha 1 AntitrypsinFig. 2Primary and secondary structure of AAT. While the top row sequence represents Uniprot numbering including the signal peptide, the bottom sequence row uses the conventional numbering for AAT found in the broad literature, and used throughout this manuscript. Color coding of residues are according to chemical properties, and display of secondary structural elements (arrow for β-strand, curl for α-helix as extracted from PDB code 1OPH) are shown above the sequences using the software package ESPript \[[@CR13]\]. The positions of the novel alleles reported in this manuscript are marked by an asterisk below the residue, and include the variant residue found. Those that are probably or possibly deleterious are colored red, and those that are possibly or probably neutral are colored green. Numbering of the variants, apart from I9N, does not include the 24 amino acid precursor. AAT, Alpha 1 Antitrypsin

### Predicting pathogenicity {#Sec6}

For all missense SNVs, NGS sequencing information was inputted into a support vector machine (SVM) model. This model combines multiple features, including both sequence- and structure-based information, to calculate the probability that a given missense change is pathogenic \[[@CR14]\]. The SVM score is in the range of zero to 1.0, with a threshold for a deleterious change set at a value of 0.5 and above. Further details concerning the SVM model utilized are outlined in the Additional file [1](#MOESM1){ref-type="media"}.

In addition to the SVM predictions, two other computational predictors of pathogenicity were utilized. First, Gibbs free energy changes (ΔΔG) associated with amino acid substitutions were calculated using the PositionScan function of the FoldX suite \[Centre for Genomic Regulation, Barcelona, Spain\] \[[@CR15]\]. ΔΔG is the difference in free energy (in kcal/mol) between a mutant and wildtype protein. A mutation with ΔΔG \> 0 will destabilize the structure, while a mutation with negative ΔΔG stabilizes the structure. A common threshold used to indicate that a mutation has a significant destabilizing effect is ΔΔG \> 1 kcal/mol \[[@CR16]\], and was therefore set as the threshold for pathogenicity in the present report. Second, PolyPhen-2 program (<http://genetics.bwh.harvard.edu/pph2/index.shtml;> version 2.2.2, Harvard University, Cambridge, MA) was also used to predict the pathogenicity of all missense SNVs. PolyPhen-2 uses an iterative greedy algorithm, informed by exposure to known damaging and non-damaging SNVs, and calculates the Naïve Bayes posterior probability that a given mutation is damaging \[[@CR17]\]. The Polyphen-2 score, also with a range of zero to 1.0 (but often stated as a percentage), has a qualitative ternary classification. Scores of 0.85, 0.85--0.15, and 0.15 are typically coded as "probably damaging", "possibly damaging", and "benign", respectively.

Scores for all three predictive methods (SVM, FoldX, and PolyPhen-2) were grouped into the following classifications: probably deleterious (all three predictions as deleterious), possibly deleterious (two of the three predictions as deleterious), possibly neutral (only one of the three predictions as deleterious), or probably neutral (none of the three predictions as deleterious).

### Benchmarking analysis of SVM predictions {#Sec7}

We confirmed the effectiveness of the SVM method by performing benchmarking analysis against two datasets of known human *SERPINA1* pathogenic and benign variants sourced from ClinVar \[[@CR18]\], and a third dataset composed of primate neutral variants (owing to the low number of benign human variants identified \[*N* = 6\]). To build the dataset of primate neutral variants, we ran PSI-BLAST with the Alpha 1 Antitrypsin (*SERPINA1*, A1AT_HUMAN) sequence as a query against a database of primate sequences from Uniprot (<http://www.uniprot.org/>). For each alignment, we identified all sequence differences between the human and primate sequence and filtered out sequence variants that were not surrounded by 2 conserved residues on either side (human and primate identical) and those adjacent to gaps within 3 residues. For each mutant, we used the search result with the highest sequence identity for that variant. In this manner we chose sequence variants that exist in the closest homologues first. We also checked the contacts of the human residue for each mutation in *SERPINA1* structure PDB: 3NE4 and filtered out sequence variants with one or more different contact residues. A contact is defined as a residue with at least one atomic distance less than 5 Å. This resulted in 35 neutral sequence variants garnered from primates with greater than 90% sequence identity.

### Measurements of binary prediction of SERPINA1 variants {#Sec8}

To further compare the accuracy of SVM predictions vs. PolyPhen-2, a number of statistical parameters were calculated. From the benchmarking data, we are able to obtain the number of true positives (TP), false positives (FP), true negatives (TN), and false negatives (FN). From these, we calculated the true positive rate (TPR), true negative rate (TNR), positive predictive value (PPV), and negative predictive value (NPV).
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*Negative predictive value* (NPV): The proportion of predicted negatives that are predicted correctly.$$\documentclass[12pt]{minimal}
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*Total accuracy* (ACC): The proportion of true results (both true positives and true negatives) among the total number of experimental cases.$$\documentclass[12pt]{minimal}
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*Balanced accuracy* (BACC): This is the average of true positive rate (TPR) and true negative rate (TNR).$$\documentclass[12pt]{minimal}
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Results {#Sec9}
=======

Patient characteristics {#Sec10}
-----------------------

Patient characteristics (*n* = 23), including AATD phenotype, AAT level, and sequencing findings, are displayed in Table [1](#Tab1){ref-type="table"}. The male:female ratio was approximately 1:1, the age range was 34--87 years, and AAT levels ranged from 2 mg/dL to 160 mg/dL.Table 1Overview of patient characteristics and rare/novel sequence variants identified by next-generation sequencingPatient IDAAT serum level (mg/dL)CRP (mg/dL)Previous phenotypesAge (yrs)SexNGS DNA analysisNovel mutant nucleotide changesConsequenceGenotypeSplice variants 2250705.9--65FNovel splice variant: G \> C at position +1 of intron 1CE376D -- M3 allele 2402362.8--71M917 + 1G \> AAffects the normal mRNA splicing.E376D -- M3 alleleDeletions 10724527.3M349MA347fs: Novel 1 bp deletion (1112delC) at position 347Frameshift that extends the protein by 5 amino acidsE376D -- M3 alleleStop codons 6326^e^20Z/M157FQ156X: C \> T at Chr14:94849037 (GRCh.37.p13) c.538C \> TInsertion of stop codon at position 156Q156X E342K -- Z allele V213A -- M1 allele 6376^e^987I54MQ156X: C \> T at Chr14:94849037 (GRCh.37.p13) c.538C \> TInsertion of stop codon at position 156Q156X R39C -- I allele 1977191.4--M57G192Fs: 1 bp deletion at Chr14:94847477 (GRCh37.p13) c.647_647delGPredicted to produce a premature stop codon at amino acid 214, leading to a premature termination on exon IIISingle-nucleotide variations CA97112--M3 M2/465FGAG \> AAGE204K -- rare^a^ E376D -- M3 alleleR101H -- M2/M4 allele 114472--M161MCCC \> TCCP289S -- rare^a^ V213A -- M1 allele 2343863.6M160FATC \> AACI9N \[includes precursor\] -- rare^a^ V213A -- M1 allele 4293^d^660.5M154MCCC \> CTCQ~0Bellingham~ -- insertion of stop codon at position 156P28L -- rare^a^ K217X -- Q0~Bellingham~ V213A -- M1 allele 5564^d^671.6M151FCCC \> CTCQ~0Bellingham~ -- insertion of stop codon at position 156P28L -- rare^a^ K217X -- Q0~Bellingham~ V213A -- M1 allele 4668782.2M362MATC \> AACI50N (Pi~Tijarafe~) -- rare E376D -- M3 allele 9533730.9--60MATG \> ACGM385 T -- rare^c^ M allele 10889--12.5M334FCAG \> CGGQ40R -- rare^a^ E376D -- M3 allele 12642890.6M366FGAC \> CTCD341V -- rare^b^ E376D -- M3 allele P = L118 -- no amino acid change 14271470.6Z/M161FATG \> ACGM221 T -- rare^a^ V213A -- M1 allele E342K -- Z allele 15230341Z/M172MGTG \> GAGV210E (N~cambodia~/Pierre-bénite) -- rare^a^ V213A -- M1 allele E342K -- Z allele 17,6571601.5M3/M487MAAG \> GAGK174E -- NOVEL^a^ E376D -- M3 allele R101H -- M2/M4 allele 21034121.2----47FCCC \> CACP369H -- rareE264V -- S allele 2163688.4----58MGTG \> ATGV333 M -- rare^c^ E376D -- M3 allele R101H -- M4 allele 23523118.6----48FGCA \> CCAA325P (Nvestenanova) -- rare^a^ R223C -- F allele E376D -- M3 allele R101H -- M4 allele 2431979.3----57FGCC \> GACA142D -- rare^c^E264V -- S allele V213A -- M1 allele 7643074.8----59MCAC \> TACH262Y -- rare^c^ M alleleAll SNVs are reported without the 24 amino acid precursor unless otherwise stated^a^SNVs have been previously reported in dbSNP (E204K -- rs199422208; P289S -- rs779938258; Q40R -- rs763483402; M221 T -- rs766260108; K174E -- rs766034720; I9N \[includes precursor\] -- rs1296175763; P28L -- rs944607375)^b^SNVs have been previously reported in dbSNP and linked to AATD (D314V -- rs864622046)^c^SNV previously reported in the literature (20--26) (H262Y -- rs149537225; V333 M -- 373,630,097; A142D -- rs142942004; V210E -- rs746197812; M385 T -- rs1488213352; A325P -- rs376024688; I50N -- rs1275309068)^d^Familial samples from brother (4293) and sister (5564)^e^Familial samples from brother (6376) and sister (6326)*bp* Base pair, *dbSNP* Database of single nucleotide polymorphisms, *SNV* Single nucleotide variation

Clinical information on disease presentation was available from the four patients referred via Lewis Katz School of Medicine: patient CA97 presented with a cerebral aneurysm, patient 1144 presented with evidence of emphysema, and patient 4668 presented with chronic inflammatory demyelinating polyneuropathy (CIDP) in addition to emphysema. In addition, patient 76430 presented with severe emphysema/COPD and bronchiectasis. Detailed clinical descriptions of these patients will be reported separately. The remaining patients were referred to the DNA~1~ Advanced Alpha-1 Screening™ program by the treating physician due to clinical presentation or symptoms potentially indicative of AATD; i.e., COPD, asthma, emphysema, panniculitis, cerebral aneurysm, or liver disease.

*SERPINA1* mutations {#Sec11}
--------------------

In this patient cohort, NGS DNA analysis identified 21 separate rare/novel variants. All amino acid changes are reported without the 24 amino acid precursor unless otherwise stated. The following variant types were identified: splice variants (*n* = 2), base pair deletions (*n* = 1), base pair changes resulting in a stop codon (n = 2; one stop codon was found in two patients), and SNVs (*n* = 16; one novel SNV \[P28L\] was found in two patients) (Table [1](#Tab1){ref-type="table"}).

### Splice variants {#Sec12}

A novel splice variant (G \> C) was discovered at position + 1 of intron 1C. The mutation occurred in a patient with no other *SERPINA1* variants but with a low AAT level of 70 mg/dL. A further splice variant (6326c.917 + 1G \> A), which resulted in an even lower AAT level of 62.6 mg/dL, was discovered in patient 24023.

### Base pair deletions {#Sec13}

A single base-pair deletion was observed in patient 10724, with a low AAT level of 52 mg/dL. The base pair deletion added 5 heterologous amino acids beyond position 347 before a stop codon, as well as truncating the remainder of the protein.

### Stop codons {#Sec14}

Sequence variants in two siblings (patients 6326 \[female\] and 6376 \[male\]), resulted in the insertion of a stop codon at position 156 (stop codon in normal AAT is position 418). Both had additional, well known pathogenic alleles: E342K (Z allele; patient 6326) and R39C (I allele; patient 6376). Combination with the Z allele in patient 6326 resulted in extremely low serum AAT levels (2 mg/dL). A further patient (ID 19771) was found to have a premature stop codon at amino acid 214, which resulted in an AAT level of 91.4 mg/dL.

### SNVs {#Sec15}

Of the 16 rare/novel SNVs found in this investigation, two (found in patients 14271 and 15230) were heterozygous for the known pathogenic Z allele. In addition, two patients (21034 and 24319) were heterozygous for the known pathogenic S allele, and a further patient (23523) was heterozygous for the known pathogenic F allele. One novel SNV occurred twice in siblings (patients 4293 \[male\] and 5564 \[female\]) in combination with the known, rare, pathogenic Q~0bellingham~ variant. The remaining novel SNVs (*n* = 10) were heterozygous with the normal M allele or M subtypes (M1, M2, M2/4, etc.), which are secreted in similar concentrations and are comparable in function to the wildtype protein.

Computational analysis of SNVs {#Sec16}
------------------------------

Computational predictions are presented in Table [2](#Tab2){ref-type="table"}. Overall, the agreement between the SVM analysis and the additional computational predictors (FoldX and PolyPhen-2) was strong for all but two SNVs. Exceptions were the Q40R (patient 10889) and H262Y (patient 76430) sequence variants -- both were associated with moderate deleterious scores by SVM (0.6589 and 0.6708, respectively), but the sequence variants were not predicted to destabilize the protein (i.e., they had small negative ΔΔG scores that indicate minor stabilization) and were predicted as benign by Polyphen-2.Table 2Summary of computational analysis of rare/novel SNVsPatient IDNovel mutationAmino acid changeAnalysisSVM probabilityΔΔG (FoldX)PolyPhen-2 ScoreComparison with previous computational characterizationsComments on side chain structureProbably deleterious mutations 1144P289S^a^Proline (P; non-polar side chain) \> serine (S; polar uncharged side chain)**0.82823.491.000**• Giacopuzzi et al. (2018) \[[@CR19]\] REVEL: **0.901**• VEST3: **0.951**• iFISH: **0.9866**• MutationAssessor: 4.425 (high)• SIFT: **0**• Tightly packed side chain buried in the same hydrophobic region as M221, in the breach at the top of the A-sheet, and the beginning of the RCL• Serine is not tolerated sterically as it is larger -- likely causing disruption to role of this strategic portion of the protein 4668I50NIsoleucine (I; hydrophobic side chain) \> asparagine (N; polar uncharged side chain)**0.81532.691.000**Giacopuzzi et al. (2018) \[[@CR19]\]• REVEL: **0.873**• VEST3: 0.706• iFISH: **0.9825**• MutationAssessor: 4.41 (high)• SIFT: **0**• Highly conserved residue• Polar side chain introduced to a very hydrophobic core of the protein• Will destabilize hydrophobic core 12,642D341VAspartic acid (D; negatively charged side chain)\>valine (V; hydrophobic side chain)**0.86510.990.998**Giacopuzzi et al. (2018) \[[@CR19]\]• REVEL: **0.599**• VEST3: 0.765• iFISH: **0.9823**• MutationAssessor: 4.06 (high)• SIFT: **0.001**• Conserved residue• Borderline significant change in protein stability• In a buried location found at the "Breach" region of the protein at the base of the RCL loop• Change to valine would eliminate aspartic acid hydrogen bonding to adjacent K343 and possibly affect RCL conformation 14,271M221 TMethionine (M; hydrophobic side chain)\>threonine (T; polar uncharged side chain)**0.81862.930.997**Giacopuzzi et al. (2018) \[[@CR19]\]• REVEL: **0.933**• VEST3: 0.778• iFISH: **0.9826**• MutationAssessor: 4.74 (high)• SIFT: **0.001**• Highly conserved residue• Tightly packed side chain buried in hydrophobic region in the breach at top of α-sheet and beginning of RCL• Threonine would be sterically tolerated due to smaller size but would not have same impact as Methionine on tight packing in strategic area of protein 15,230V210EValine (V; hydrophobic side chain)\>glutamic acid (E; negatively charged side chain)**0.71621.370.818**Giacopuzzi et al. (2018) \[[@CR19]\]• REVEL: **0.752**• VEST3: 0.618• iFISH: **0.9338**• MutationAssessor: 3.745 (high)• SIFT: **0.002**• Not a highly conserved residue• Residue participates in tight hydrophobic packing near the tip of a β--strand hairpin• Introduction of glutamic acid could cause charge repulsion with D211 and disrupt packing of β-hairpin or could introduce a new h-bond with nearby N390 4293†& 5564†P28L^a^Proline (P; non-polar side chain)\>leucine (L; hydrophobic side chain)**0.82051.170.648**Giacopuzzi et al. (2018) \[[@CR19]\]• REVEL: 0.387• VEST3: 0.404• iFISH: 0.7976• MutationAssessor: 2.86 (medium)• SIFT: **0.038**• Highly conserved residue• P28 is near the N-terminus and the side chain packs against P23.• Change to the larger hydrophobic leucine would be sterically permissible as the side chain is surface-accessible.• Possible that the wildtype Proline is necessary to kink the helix for the tight packing to occur, and the conformation of N-terminal helix interaction with the rest of the protein 21,034P369HProline (P; non-polar side chain)\>histidine (H; positively charged side chain)**0.87843.361.000**Giacopuzzi et al. (2018) \[[@CR19]\]• REVEL: **0.834**• VEST3: **0.945**• iFISH: **0.9877**• MutationAssessor: 4.755 (high)• SIFT: **0**• Buried location found at end of the RCL loop• Change to histidine would disrupt packing and affect RCL conformation 24,319A142DAlanine (A; small hydrophobic side chain)\>aspartic acid (D; negatively charged side chain)**0.79581.030.992**Giacopuzzi et al. (2018) \[[@CR19]\]• REVEL: **0.615**• VEST3: 0.694• iFISH: **0.9591**• MutationAssessor: 3.51 (high)• SIFT: **0.003**Silva et al., (2016) \[[@CR20]\]• PolyPhen-2: **0.99**• Highly conserved residue• Change to aspartic acid could be sterically problematic as larger charged side chain is introduced to a hydrophobic pocket and could destabilize itPossibly deleterious mutations 9533M385 TMethionine (M; hydrophobic side chain)\>threonine (T; polar uncharged side chain)**0.87223.34**0.134Giacopuzzi et al. (2018) \[[@CR19]\]• REVEL: **0.668**• VEST3: 0.738• iFISH: **0.801**• MutationAssessor: 1.97 (medium)• SIFT: 0.094• Conserved residue• Residue in buried core of protein and makes at least 12 hydrophobic contacts in the core• Change to threonine would shorten the side chain and disrupt core packing; note the significant stability drop 21,636V333 MValine (V; hydrophobic side chain)\>methionine (M; hydrophobic side chain)**0.7237**−0.25**0.990**Giacopuzzi et al. (2018) \[[@CR19]\]• REVEL: **0.539**• VEST3: 0.676• iFISH: **0.8378**• MutationAssessor: 1.985 (medium)• SIFT: 0.079Silva et al., (2016) \[[@CR20]\]• PolyPhen-2: 0.53• Buried location with low ASA; found within the beta-sheet region• Larger/longer side-chain• Methionine may sterically clash in the buried locationPossibly neutral mutations 2343I9N \[includes precursor\]^a^Isoleucine (I; hydrophobic side chain) \>asparagine (N; polar uncharged side chain)0.3387N/A0.517Giacopuzzi et al. (2018) \[[@CR19]\]• REVEL: 0.453• VEST3: 0.291• iFISH: 0.3779• MutationAssessor: 1.1 (low)• SIFT: **0.001**• Not included in Fig. [1](#Fig1){ref-type="fig"} visualization (no structural information on this portion of the protein) 10,889Q40R^a^Glutamine (Q; polar uncharged side chain)\>arginine (R; positively charged side chain)**0.6589**−0.350.018Giacopuzzi et al. (2018) \[[@CR19]\]• REVEL: 0.311• VEST3: 0.092• iFISH: 0.5284• MutationAssessor: 1.515 (low)• SIFT: 0.24• Conserved residue• Change to the larger Arginine side chain would present steric problems, despite its accessibility• Q40 hydrogen bonds to V302 and while the larger side chain could also hydrogen bond, it could disrupt packing of the helix that holds V302 17,657K174E^a^Lysine (K; positively charged side chain) \>glutamic acid (E; negatively charged side chain)**0.5053**0.210.030Giacopuzzi et al. (2018) \[[@CR19]\]• REVEL: **0.622**• VEST3: 0.681• iFISH: **0.6117**• MutationAssessor: 2.24 (medium)• SIFT: 0.208• Moderately conserved residue• Change to side chain is sterically tolerated as a smaller side chain is introduced in to a solvent-accessible loop of the protein 76,430H262YHistidine (H; positively charged side chain)\>tyrosine (Y; largely hydrophobic side chain, but hydroxyl group can participate in hydrogen bonds or also be phosphorylated)**0.6708**−0.680.040Giacopuzzi et al. (2018) \[[@CR19]\]• REVEL: 0.086• VEST3: 0.144• iFISH: 0.5173• MutationAssessor: 1.54 (low)• SIFT: **0.042**Silva et al. (2016) \[[@CR20]\]• Polyphen-2: 0.06 (21)• Highly conserved residue• Tightly packed side chain buried• Histidine is involved in 3 hydrogen bonds -- to backbone atoms of residues N265, E266, K234• Tyrosine might not be tolerated sterically because it is largerProbably neutral mutations CA97E204K^a^Glutamic acid (E; negatively charged side chain)\>lysine (K; positively charged side chain)0.1021− 0.700.000Giacopuzzi et al. (2018) \[[@CR19]\]• REVEL: 0.457• VEST3: 0.648• iFISH: 0.1155• MutationAssessor: − 0.625 (low)• SIFT: 0.921• Not a conserved residue, larger lysine chain is sterically tolerated & can make similar contacts.• Little change in protein stability is predicted. Although variant could affect RCL from a distance 23,523A325PAlanine (A; small hydrophobic side chain)\>proline (P; non-polar side chain)0.08780.720.000Giacopuzzi et al. (2018) \[[@CR19]\]• REVEL: 0.214• VEST3: 0.143• iFISH: 0.4862• MutationAssessor: 0.265 (medium)• SIFT: 0.411• Not conserved• Insignificant change in protein stability• In a surface-accessible loop, that could play a role in an alternate trypsin binding siteAll sequence variants are reported without the 24 amino acid precursor unless otherwise stated; ^a^variants previously reported in the dbSNP onlyComputational analysis (excludes MutationAssessor): numbers in bold, deleterious score; numbers in normal text, neutral score; *RCL* Reactive center loop, *SVM* Single vector machine, *ASA* Accessible surface area

### Probably deleterious variants {#Sec17}

Eight sequence variants were classified as probably deleterious (i.e., all three predictors registered a deleterious score). Two patients (14271 and 15230) were found to have novel mutations, M221T and V210E, respectively, in combination with the Z allele. Computational analyses strongly suggested that both novel sequence variants were deleterious. The AAT levels found in these samples (47 and 34 mg/dL, respectively) were lower than would be expected for an individual with the PI\*MZ genotype \[66--100 mg/dL\] \[[@CR8]\] and were around the range of an individual homozygous for the Z allele \[20--45 mg/dL\] \[[@CR1]\]. Additionally, two siblings (patients 4293 and 5564) presented with low AAT levels and a highly unusual genotype -- the known pathogenic rare mutation Q0~bellingham~ was accompanied by the novel mutation P28L, which all three computational analyses predicted to be damaging.

Most of the remaining rare/novel SNVs that the computational analyses predicted to be probably pathogenic were heterozygous with normal alleles. The presence of the P289S (patient 1144), I50N (patient 4668), D341V (patient 12642), or A142D (patient 24319) sequence variants appeared to result in AAT levels ranging from 72 to 89 mg/dL -- levels that are often associated with PI\*MZ individuals. Moreover, patients 1144 and 4668, who presented with the P289S and I50N mutations, respectively, were recorded as having lung disease.

There was only one exception from the general agreement between computational predictions and AAT serum levels -- the P369H mutation, observed in patient 21034. All three computational analyses predicted the mutation to be highly deleterious; however, the AAT serum level was normal (121.2 mg/dL). This may have been due to the presence of an inflammatory state at the time of sampling; unfortunately, a CRP value was not available for this patient.

### Possibly deleterious variants {#Sec18}

Two sequence variants were classified as possibly deleterious (i.e., two of three predictors registered a deleterious score). The variant M385 T (patient 9533) was found in combination with a wildtype allele. The M385 T variant is a good example of how methods that focus on a variety of structural parameters for prediction may be more effective than those that more heavily weight sequence conservation. Both the SVM deleterious result and the FoldX prediction of a significant drop in stability make this variant likely deleterious. These predictions correspond to an AAT level of 73 mg/dL, which was likely to be mainly contributed by the wildtype (normal) allele in this patient. While Polyphen-2 predicted the M385 T variant to be benign, the added structural information considered by both the SVM and FoldX predictors contributed to a greater sensitivity to detect this variant as deleterious. Lastly in this category, the variant V333 M (patient 21636) was found in combination with M3 and M4 alleles and a serum level of 88.4 mg/dL. The SVM and Polyphen-2 predictions were deleterious, while the FoldX score predicted no destabilization of the protein.

### Possibly neutral variants {#Sec19}

Four sequence variants were predicted to be possibly neutral (only one of the three predictors scored as deleterious). The I9N (includes precursor) found in patient 2343 was classified as possibly neutral as the SVM prediction (0.3387) was below the deleterious threshold, accompanied by a borderline pathogenic score (0.517) from PolyPhen-2, and a moderate AAT level of 86 mg/dL. As this mutation is in the cleaved precursor region of AAT and as there are no coordinates for this residue in the protein structure, a Gibbs free energy change cannot be calculated. The Q40R variant had an SVM score of 0.6589 (a moderately deleterious result), but was not predicted to destabilize the protein, and scored benign by Polyphen-2. This variant was accompanied by a second M3 allele, and serum AAT levels were not obtained for the patient (10889). A novel mutation from patient 17657 (K174E) was predicted by SVM to have a borderline deleterious score of 0.5053; however, the score had ±0.036 standard deviation and could thus potentially be below the threshold for deleterious. This was accompanied by benign predictions by FoldX and Polyphen-2, and was associated with normal AAT levels (160 mg/dL). The H262Y variant (patient 76430) was associated with a moderate deleterious prediction by SVM (0.6708), but was not predicted to destabilize the protein, and was predicted benign by Polyphen-2. Nonetheless, the low serum AAT level of 74.8 mg/dL found in this patient accompanied by the presence of lung disease are suggestive of deleterious effects.

### Probably neutral variants {#Sec20}

In this last category, two variants were predicted to be probably neutral (i.e., none of the three predictors scored as deleterious). One mutation in a non-conserved residue (E204K) found in patient CA97 was predicted to be neutral by all predictors -- this is supported by the normal AAT level found in this patient (112 mg/dL). Similarly, the A325P mutation (patient 23523) was accompanied by a normal AAT level of 118.6 mg/dL, with agreement among the three predictions that the mutation was neutral.

Benchmarking of SVM predictions {#Sec21}
-------------------------------

Table [3](#Tab3){ref-type="table"} provides the SVM predictions for each of the benign and pathogenic variants included in the benchmarking analysis, with comparisons to PolyPhen2 and FoldX predictions. For the pathogenic variant set, 17/17 (100%) were predicted to be deleterious by SVM, and correspondingly 16/17 variants (94.1%) were predicted to have negative effects on stability of the protein by FoldX. PolyPhen2 predicted 16/17 (94.1%) to be pathogenic. For the benign ClinVar set, 5/5 variants (100%) were predicted by both the SVM and PolyPhen-2 to be benign, and correspondingly 4/5 were predicted by FoldX to slightly improve protein stability (negative values indicate better predicted stability with the variant). In the alternative benign primate dataset, 28/35 variants (80%) were predicted to be benign by the SVM, compared with 32/35 predicted (91.4%) predicted to be benign by PolyPhen-2. The statistical parameters calculated suggest that the accuracy of both SVM and PolyPhen-2 predictors are broadly similar (Table [4](#Tab4){ref-type="table"}). While the sample sizes of this benchmark set are not sufficient for a comprehensive comparison of the SVM to Polyphen-2 or other predictors, overall the benchmark testing on these variants of known effect on *SERPINA1* function validates the strength and accuracy of the SVM and Polyphen-2 for predictions on novel variants presented in this work.Table 3Results of benchmarking analysis*SERPINA1* mutationSpeciesSequence Identity (%)SVM probabilityΔΔG (FoldX)PolyPhen-2 ScorePathogenic sequence variants (ClinVar) P369L*Homo sapiens*100**0.84961.5101.0000** P369SHomo sapiens100**0.83534.4101.0000** P369THomo sapiens100**0.85992.8101.0000** M358RHomo sapiens100**0.7853**0.4310.0190 E342KHomo sapiens100**0.84132.0901.0000** E264VHomo sapiens100**0.86191.6601.0000** D256VHomo sapiens100**0.87081.9500.9850** G225RHomo sapiens100**0.89755.1600.9820** R223CHomo sapiens100**0.8954**−0.350**0.9950** I92NHomo sapiens100**0.82153.6001.0000** G67EHomo sapiens100**0.868026.2901.0000** S53FHomo sapiens100**0.868719.8601.0000** L41PHomo sapiens100**0.75853.2400.6010** R39CHomo sapiens100**0.86722.1101.0000** A336THomo sapiens100**0.84793.4501.0000** G115SHomo sapiens100**0.78261.6100.9990** F52SHomo sapiens100**0.79006.0201.0000**Benign sequence variants (ClinVar) E376DHomo sapiensN/A0.2991**1.850**0 E363KHomo sapiensN/A0.4172−0.9000.11 A284SHomo sapiensN/A0.3445−0.2400.139 V213AHomo sapiensN/A0.1161−0.1000 R101HHomo sapiensN/A0.0576−0.5330Benign sequence variants (Primate neutral variants) P21QHylobates sp. ECACC95*0.3630.72*0.014 F23LPapio anubis920.37620.380 T27A*Gorilla gorilla*980.4118**1.34**0 N29KHylobates sp. ECACC950.4365−0.630.178 N29SPapio anubis920.08390.130 T48SHylobates sp. ECACC950.49910.510 I50VGorilla gorilla98**0.6687***0.96***0.767** D74SChlorocebus sabaeus920.05880.380 N81HPongo abelii960.4620.270.007 I92VPongo abelii; Hylobates sp. ECACC96; 95**0.7931***1.06*0.006 Q105KPapio anubis920.2178−0.50.001 N116SGorilla gorilla98**0.7511.9**0.311 K136NPapio anubis920.42920.070 E141DPongo abelii960.40520.770.002 G148EChlorocebus sabaeus920.219−0.460 D159NPapio anubis920.165−1.210 Q212EPongo abelii960.25680.350 V213AHylobates sp. ECACC950.1161−0.10 Q230YPapio anubis920.08030.490 Q230HHylobates sp. ECACC950.05450.410 K233EPapio anubis920.07870.580 D270EHylobates sp. ECACC950.2543−0.030 I271VGorilla gorilla980.10150.520 D280NPongo abelii960.1407*0.82*0 S285NChlorocebus sabaeus920.0554−1.60 S292AChlorocebus sabaeus920.3206−0.140.003 S301RPongo abelii960.1328−0.540.011 S301THylobates sp. ECACC950.072400 S313GHylobates sp. ECACC95**0.606***0.63*0.05 E324DChlorocebus sabaeus920.0978*0.62*0 A332VHomo sapiens990.1255**1.880.99** I360VGorilla gorilla980.1547*0.73*0 L383HHylobates sp. ECACC95**0.88343.081** M385IPapio anubis92**0.76863.15**0.001 M385 V*Pan troglodytes*; Pongo abelii99; 96**0.75662.44**0.001All variants are reported without the 24 amino acid precursor unless otherwise statedScores in bold, pathogenic; scores in italics, possibly pathogenic; scores in normal text, benign. *SVM* Support vector machineTable 4Measurements of benchmarking predictionsTPR (sensitivity)TNR (specificity)PPVNPVACCBACCSVM1.00.8250.7201.00.8790.913Polyphen20.9440.9250.850.9740.9310.935*TNR* True negative rate, *TPR* True positive rate, *PPV* Positive predictive value, *NPV* Negative predictive value, *ACC* Total accuracy, *BACC* Balanced accuracy

Discussion {#Sec22}
==========

Through the DNA~1~ Advanced Alpha-1 Screening™ program, we have begun to encounter large numbers of novel sequence variants of the *SERPINA1* gene, as evidenced by the data we have presented. The present study is supportive of several earlier investigations that have uncovered previously uncharacterized and potentially pathogenic sequence variants of *SERPINA1* \[[@CR7], [@CR9], [@CR12], [@CR19], [@CR21]\]. There is a growing body of evidence to suggest that novel sequence variants may be more clinically impactful than previously thought, with some reported to be associated with early onset COPD \[[@CR9]\].

Using NGS, we identified 21 rare/novel sequence variants of the *SERPINA1* gene in patients suspected of having AATD. Most of the variants (*n* = 16) were SNVs. In addition, two base pair changes resulting in stop codon insertions, one base pair deletion, and two splice variants were discovered. All of the SNVs were previously recorded in the National Center for Biotechnology Information's database of single nucleotide polymorphisms (dbSNP) and/or in the literature \[[@CR19], [@CR20], [@CR22]--[@CR26]\] (Table [1](#Tab1){ref-type="table"}). The I50N variant (Pi~Tijarafe~) was previously confirmed as pathogenic in an vitro cell model, and was associated with similar AAT expression to the Z variant \[[@CR26]\]. Nonetheless, to the best of our knowledge, this is the first study to describe seven variants (E204K, P289S, Q40R, M221T, K174E, I9N \[includes precursor\] and P28L) alongside additional patient data. However, despite the availability of other data such as AAT levels, determining whether these variants are clinically relevant is challenging. We therefore sought to evaluate the utility of computational modeling to provide supporting evidence, in addition to observed AAT serum levels, of the pathogenicity of rare SNVs. We note that computational methods predict the effects of missense variants on either protein function (SVM, and machine learning approaches) or the inherent stability of the tertiary/quaternary structure of a protein (FoldX). However, this may not always correspond with clinical parameters, such as secreted protein serum levels, or the degree of pathogenicity in a particular organ.

The majority of the sequence variants identified in our cohort were predicted to be deleterious by computational methods. Only two variants were predicted to be probably neutral by all three computational techniques. Of the rare variants previously reported in the dbSNP only (E204K, P289S, Q40R, M221T, K174E, I9N \[includes precursor\] and P28L), the probably deleterious variants were predicted to be, P289S, M221T, and P28L, and were accompanied by low AAT levels. In particular, the P289S variant was found in a 61-year-old patient with advanced emphysema, supporting the pathogenicity of this variant. The remaining variants were predicted to be neutral or possibly neutral, and were accompanied by normal or low-normal AAT levels (although no AAT level was reported with the Q40R variant), and are less likely be clinically relevant. Although there is some evidence of a relationship between AAT variants and cerebral aneurisms \[[@CR27]\], we do not have sufficient evidence to conclude a causal relationship between the clinical presentation in patient (CA97) and the E204K variant. For the rare variants predicted to be probably deleterious or possibly deleterious, in line with previous reports, we observed that the majority of these cluster around functional domains of AAT \[[@CR20]\]. The mechanism of pathogenicity for most of these sequence variants (I50N, P289S, M385T, M221T, D341V, V210E, P369H, V333M and A142D) is likely to be via disruption of the tightly packed hydrophobic core of the AAT protein, and some may in turn disrupt the adjacent reactive center loop (RCL; Fig. [3](#Fig3){ref-type="fig"}) that inhibits proteases. One possible mechanism is that substantial changes to the core of the protein could result in misfolding of the protein within hepatocytes, such that only small amounts of AAT would be released, resulting in reduced levels of AAT in the peripheral circulation. An alternative mechanism of pathogenicity might include missense changes that do not affect AAT folding and result in normal levels detected in serum, but have a deleterious effect on conformational changes required for sheet opening or protein-protein interactions necessary for inhibition of neutrophil elastase.Fig. 3Structure of AAT zoomed in on locations of interest. Presented are some of the missense residues predicted to negatively affect the stability of the folded protein. Several of these missense changes are in the tightly packed core of the protein, such as the P289S variant packed tightly near the M221T variant location

As expected, very low blood levels of AAT were found in heterozygotes for known deficiency alleles and new mutations. Two patients (12230 and 15230) in this study had very low AAT levels around the range associated with a PI\*ZZ individual \[20--45 mg/dL\] \[[@CR1]\], and novel pathogenic variants in combination with the Z allele. Patients such as these would be strong candidates for AAT therapy if they presented with airflow obstruction and significant emphysema \[[@CR28]\]. There are more than 6 million individuals in the United States alone with the PI\*MZ genotype \[[@CR5]\]. As shown by this study, it is possible that numerous other patients may be undiagnosed compound heterozygotes with rare/novel sequence variants not detectable by IEF or targeted genotyping. The concept of cumulative deleterious effects in compound heterozygotes has previously been described for the PI\*FZ genotype \[[@CR29]\]. The F allele is associated with normal AAT levels but reduced AAT functionality, while low circulating levels are observed in Z patients \[[@CR29]\]. All AAT secreted by PI\*FF homozygotes has reduced functionality and these individuals have been shown to be at increased risk of lung damage caused by uninhibited elastase \[[@CR29]\]. In PI\*FZ heterozygotes, functionality and circulating levels are both reduced, resulting in an increased risk of emphysema compared with PI\*FF patients \[[@CR29]\].

Most novel sequence variants within our cohort were heterozygous with normal variants; it is therefore difficult to fully assess the impact of these variants on serum AAT levels and risk of emphysema. For known variants the disease risk is well known. For example, individuals with the PI\*MZ genotype have a greater degree of airflow obstruction than PI\*MM individuals with comparable smoke exposure, and ever-smoking PI\*MZ individuals have an increased risk of developing COPD \[[@CR30]\]. However, the longitudinal disease-risk associated with rare alleles is unknown and AAT levels, although indicative of severity, are not conclusive. As the majority of these rare/novel variants will probably have different mechanisms of pathogenicity, it is possible that the disease risk is different to that of common heterozygotes and is specific for each variant. Further biochemical and clinical characterization is needed to fully understand how these sequence variants contribute to lung disease.

AATD is usually associated with single amino acid substitutions/deletions leading to subtle structural changes to the AAT protein; however, this study also identified splice variants, stop codons, and large deletions in *SERPINA1*. The potential contribution of these sequence variants to AATD should not be underestimated, especially when occurring in combination with damaging structural mutations. For example, in patient 6326, insertion of a stop codon at position 156 in combination with the Z mutation resulted in a severe reduction in antigenic AAT levels (2 mg/dL). This effect was not apparent in this patient's sibling (patient 6376), whose AAT level was 98 mg/dL. Patient 6376 is heterozygous for the above mentioned stop codon and the PI\*I (R39C) allele -- the PI\*I mutation gives rise to a misfolded AAT protein, which is present in peripheral blood at near-normal concentrations \[[@CR31]\]. This further demonstrates that rare and novel sequence variants can become more clinically relevant in combination with common deficiency alleles.

For patients with rare/novel mutations, apart from instances where the variants are deletions or null variants, it can be difficult to determine the impact of sequence variants and if treatment with exogenous AAT is necessary. This study has demonstrated that computational analyses may be useful in understanding the potential impact of novel mutations. The three predictive computational methods presented were generally in agreement and in most cases related to the observed AAT levels. In particular, we found that the enhanced structural information that contributes to the SVM predictions may confer a greater sensitivity to deleterious variants, making it suited for clinical genetics applications. The benchmarking analysis provides a strong validation for the balanced accuracy of the SVM predictions and supports its use in predicting the effects of the novel variants described in the current work. In addition, there was good agreement between results of the present analysis and previous studies \[[@CR19], [@CR20]\] (Table [2](#Tab2){ref-type="table"}). One exception to the general agreement between this and previous studies may be P28L, with other computational measures suggesting that it is of intermediate pathogenicity. However, it is notable that the number of previously reported deleterious scores generally mirror that of those reported in the present study through the categories of probably deleterious, possibly deleterious, possibly neutral and probably neutral utilized in the present study. In particular, in the probably neutral section, no deleterious scores are presented from this analysis or previous reports.

Some important limitations of this study should be mentioned. This observational study was not controlled, i.e., there were no formal inclusion and exclusion criteria and no control group, and data were collected from a small (*N* = 23) patient population. In addition, genetic and non-genetic factors -- not related to the AAT sequence variants reported here -- may have contributed to the development of COPD. However, these factors are beyond the scope of the current report. Furthermore, computational modeling of missense variants only predicts if a substitution is deleterious to protein function or stability. We do not know the exact mechanisms by which these substitutions lead to either reduced AAT levels or weakened elastase-inhibiting activity. Furthermore, it should be noted that a host of different modeling software are available, and each may produce different results for a particular mutation, as demonstrated by Giacopuzzi et al. (Table [2](#Tab2){ref-type="table"}). It was outside the scope of the present study to assess a wide range of modeling techniques, as a further aim of the study was to relate the computational scores to clinical parameters. However, Giacopuzzi et al. raise an important point, in that no individual computational method is infallible, and in an ideal situation, more than one technique should be consulted in the clinical decision-making process. In addition, computational predictions may be inconsistent with findings of experimental characterization; therefore, ultimately, detailed biochemical functional analysis of the protein is required to validate the findings of computational analyses. In addition, clinical information on patient presentation is required in order to obtain a full picture of the patient's individual disease risk.

Despite the above limitations, this study demonstrates that there are numerous potentially pathogenic novel variants beyond those commonly associated with AATD. Due to the progressive and irreversible destruction of lung tissue seen in severe AATD, early and accurate diagnosis is crucial to prevent further loss of lung tissue. Data from the RAPID/RAPID Extension trials has demonstrated that while treatment with AAT can slow the loss of lung tissue, tissue lost prior to commencing treatment cannot be regained \[[@CR32], [@CR33]\]. This is compounded by the fact that patients often experience long delays before receiving an accurate diagnosis \[[@CR34]\], partly due to a lack of specialized testing. Early diagnosis also enables patients to implement lifestyle changes such as smoking cessation and avoidance of passive smoke. However, identifying rare/novel variants can be difficult, and this task may be impossible by traditional methods such as protein phenotyping via IEF \[[@CR10]\].

The increasing availability of commercial DNA testing is helping to improve diagnosis of patients with AATD and rare genotypes \[[@CR35]\]. However, many current approaches do not incorporate sequencing, and are unable to detect potentially pathogenic rare/novel variants that may lead to development of AATD. The need for faster screening and diagnosis of AATD has led to the development of the DNA~1~ Advanced Alpha-1 Screening™ Program. DNA~1~ testing incorporates AAT levels, C-reactive protein serum levels, targeted genotyping (including the F and I alleles), and IEF, and reflexes to NGS when these methods prove insufficient. Our results support the proposal by Graham et al*,* who recommended that individuals with low serum levels and no resolution in targeted tests should be subjected to full-gene sequencing \[[@CR12]\].

Conclusions {#Sec23}
===========

Advancements in DNA sequencing technology continue to reveal numerous rare/novel sequence variants in the *SERPINA1* gene. Many of these variants may be pathogenic and causative factors in the development of AATD. Computational modeling opens new dimensions of structural analysis, which can help to define the pathogenic nature of these variants more accurately. The computational analyses we present are straightforward to perform and can provide a valuable additional indication (in combination with serum levels and clinical presentation) of the pathogenicity of novel mutations. We expect that this added information will eventually lead to improved individualized therapy for patients with AATD.

Additional file
===============

 {#Sec24}

Additional file 1:Protein modeling to assess the pathogenicity of rare variants of SERPINA1 in patients suspected of having Alpha 1 Antitrypsin Deficiency (DOCX 25 kb)

AAT

:   Alpha 1 Antitrypsin

AATD

:   Alpha 1 Antitrypsin Deficiency

IEF

:   Isoelectric focusing

NE

:   Neutrophil elastase

NGS

:   Next-generation sequencing

RCL

:   Reactive Center Loop

SNP

:   Single-nucleotide polymorphism

SNV

:   Single-nucleotide variation

SVM

:   Support vector machine
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